Psychopharmacologic treatment of pediatric anxiety disorders

Shauna P. Reinblatt*, John T. Walkup

*Corresponding author for this work

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

The pharmacologic treatment of pediatric anxiety disorders has historic roots, which coupled with recent advances over the last decade, has expanded evidence-based practice; however, much work still remains to be done. This article provides a practical overview of the current literature with an emphasis on the results of controlled and open trials, side effects, short- and long-term treatment strategies, and treatment-resistant illness. SSRIs seem to be the treatment of choice for most pervasive and impairing anxiety disorders in youth. Despite extensive experience with the TCAs, side effects and less overall efficacy data relegate the TCAs to second-line treatment. Although benzodiazepines have been evaluated extensively in adults, they are less commonly used in children because of better alternatives and the risk for dependency in this vulnerable population. As research on the treatment of pediatric anxiety disorders continues, our understanding of who responds best to what treatment, how to combine medication with psychosocial treatments, how long to treat to reduce the risk for relapse off medication, and the long-term safety of current medications will improve the outcome for children who suffer from these disorders.

Original languageEnglish (US)
Pages (from-to)877-908
Number of pages32
JournalChild and Adolescent Psychiatric Clinics of North America
Volume14
Issue number4
DOIs
StatePublished - Oct 1 2005

Fingerprint

Anxiety Disorders
Pediatrics
Therapeutics
Evidence-Based Practice
Vulnerable Populations
Benzodiazepines
Safety
Recurrence
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

@article{fbbd237bdf744758a3acd5a56823ae06,
title = "Psychopharmacologic treatment of pediatric anxiety disorders",
abstract = "The pharmacologic treatment of pediatric anxiety disorders has historic roots, which coupled with recent advances over the last decade, has expanded evidence-based practice; however, much work still remains to be done. This article provides a practical overview of the current literature with an emphasis on the results of controlled and open trials, side effects, short- and long-term treatment strategies, and treatment-resistant illness. SSRIs seem to be the treatment of choice for most pervasive and impairing anxiety disorders in youth. Despite extensive experience with the TCAs, side effects and less overall efficacy data relegate the TCAs to second-line treatment. Although benzodiazepines have been evaluated extensively in adults, they are less commonly used in children because of better alternatives and the risk for dependency in this vulnerable population. As research on the treatment of pediatric anxiety disorders continues, our understanding of who responds best to what treatment, how to combine medication with psychosocial treatments, how long to treat to reduce the risk for relapse off medication, and the long-term safety of current medications will improve the outcome for children who suffer from these disorders.",
author = "Reinblatt, {Shauna P.} and Walkup, {John T.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.chc.2005.06.004",
language = "English (US)",
volume = "14",
pages = "877--908",
journal = "Child and Adolescent Psychiatric Clinics of North America",
issn = "1056-4993",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Psychopharmacologic treatment of pediatric anxiety disorders. / Reinblatt, Shauna P.; Walkup, John T.

In: Child and Adolescent Psychiatric Clinics of North America, Vol. 14, No. 4, 01.10.2005, p. 877-908.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Psychopharmacologic treatment of pediatric anxiety disorders

AU - Reinblatt, Shauna P.

AU - Walkup, John T.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The pharmacologic treatment of pediatric anxiety disorders has historic roots, which coupled with recent advances over the last decade, has expanded evidence-based practice; however, much work still remains to be done. This article provides a practical overview of the current literature with an emphasis on the results of controlled and open trials, side effects, short- and long-term treatment strategies, and treatment-resistant illness. SSRIs seem to be the treatment of choice for most pervasive and impairing anxiety disorders in youth. Despite extensive experience with the TCAs, side effects and less overall efficacy data relegate the TCAs to second-line treatment. Although benzodiazepines have been evaluated extensively in adults, they are less commonly used in children because of better alternatives and the risk for dependency in this vulnerable population. As research on the treatment of pediatric anxiety disorders continues, our understanding of who responds best to what treatment, how to combine medication with psychosocial treatments, how long to treat to reduce the risk for relapse off medication, and the long-term safety of current medications will improve the outcome for children who suffer from these disorders.

AB - The pharmacologic treatment of pediatric anxiety disorders has historic roots, which coupled with recent advances over the last decade, has expanded evidence-based practice; however, much work still remains to be done. This article provides a practical overview of the current literature with an emphasis on the results of controlled and open trials, side effects, short- and long-term treatment strategies, and treatment-resistant illness. SSRIs seem to be the treatment of choice for most pervasive and impairing anxiety disorders in youth. Despite extensive experience with the TCAs, side effects and less overall efficacy data relegate the TCAs to second-line treatment. Although benzodiazepines have been evaluated extensively in adults, they are less commonly used in children because of better alternatives and the risk for dependency in this vulnerable population. As research on the treatment of pediatric anxiety disorders continues, our understanding of who responds best to what treatment, how to combine medication with psychosocial treatments, how long to treat to reduce the risk for relapse off medication, and the long-term safety of current medications will improve the outcome for children who suffer from these disorders.

UR - http://www.scopus.com/inward/record.url?scp=24944536676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944536676&partnerID=8YFLogxK

U2 - 10.1016/j.chc.2005.06.004

DO - 10.1016/j.chc.2005.06.004

M3 - Review article

VL - 14

SP - 877

EP - 908

JO - Child and Adolescent Psychiatric Clinics of North America

JF - Child and Adolescent Psychiatric Clinics of North America

SN - 1056-4993

IS - 4

ER -